--- title: Immunotherapy May Treat This Deadly Breast Cancer description: The newest immune-based therapy may be effective against triple negative breast cancer, which currently has few treatment options canonical: https://time.com/4721371/immunotherapy-triple-negative-breast-cancer/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2017-04-03T18:38:22.000Z article:modified_time: 2026-02-23T04:09:10.260Z article:section: Health og:title: Immunotherapy May Treat This Deadly Breast Cancer og:description: The disease currently has few treatment options og:url: https://time.com/4721371/immunotherapy-triple-negative-breast-cancer/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt936a5938ac00481d/698868f2cf40a8237cc4044e/breast-cancer-02.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2560 og:image:height: 1440 og:image:alt: breast cancer og:type: article twitter:card: summary_large_image twitter:title: Immunotherapy May Treat This Deadly Breast Cancer twitter:description: The disease currently has few treatment options twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt936a5938ac00481d/698868f2cf40a8237cc4044e/breast-cancer-02.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Immunotherapy May Treat This Deadly Breast Cancer > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=c65417f7-d996-4603-9a07-81adf16d953a&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | Subscribers | Open rate | | --- | --- | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | 540,000 | 45.6% | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | 430,000 | 50.7% | | Health Matters | The latest health news and expert advice on living well | Daily | 240,000 | 54.1% | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | 40,000 | 31.7% | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | 85,000 | 37.0% | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | 40,000 | 34.2% | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | 25,000 | 28.6% | Source: TIME, August 2026. Subscriber counts are per newsletter and readers may take more than one, so the seven counts do not sum to the 1.1 million+ unique newsletter audience. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Highest open rate | 54.1%, Health Matters | TIME, August 2026 | | Largest list | 540,000, The Brief | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=c65417f7-d996-4603-9a07-81adf16d953a&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=c65417f7-d996-4603-9a07-81adf16d953a&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Apr 3, 2017 6:38 PM UTC  Patient waiting on examination table Patient waiting on examination tableGetty Images (1); Illustration by Mia Tramz for TIME  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Apr 3, 2017 6:38 PM UTC Triple negative breast cancer is one of the most difficult types of cancer to treat. It lacks proteins that can attract powerful anti-cancer and hormone drugs, so people diagnosed with the disease have to rely almost exclusively on chemotherapy. But in a new presentation at the annual [American Association for Cancer Research meeting](http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105), researchers say that one of the latest [immunotherapy](http://time.com/4270345/immunotherapy-pembro-clinical-trials-cancer/) drugs called atezolizumab, or Tecentriq, may help people with triple negative breast cancer to live longer. The study, which involved women with triple negative breast cancer that had spread, did not compare people taking atezolizumab to a placebo. Rather, it looked at who responded to the drug versus who did not. All of the responders among the 112 people in the study were alive after one year, compared to 38% of those who did not respond to the drug. “This is a group of patients who are benefiting from something we couldn’t offer them a few years ago,” says Dr. Peter Schmid, professor of cancer medicine and director of the breast center at St. Bartholomew’s Breast Centre in London. Atezolizumab is an antibody that releases the brakes that the immune system puts on destroying tumor cells, which start from normal cells but grow out of control. Schmid and his colleagues found that the drug can control growth and spread of triple negative breast cancers, and the earlier women receive the treatment, the better they fare. Among those who took the drug as their first-line therapy, 26% responded. Only 10% did if they had tried some other treatments first. “It’s not where we would like it to be, but it’s a very strong signal,” says Schmid. Schmid says that he and his colleagues are working on finding ways to know which people will respond to drugs like atezolizumab and which people won’t. They’re also investigating combinations of drugs and pairing the drug with chemotherapy, tactics that may improve survival even more. They’re hopeful that better treatments are coming. “This is the most encouraging signal I’ve seen in metastatic triple negative breast cancer,” he says. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/4721371/immunotherapy-triple-negative-breast-cancer/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/4721371/immunotherapy-triple-negative-breast-cancer/"},"headline":"Immunotherapy May Treat This Deadly Breast Cancer","datePublished":"2017-04-03T18:38:22.000Z","dateModified":"2026-02-23T04:09:10.260Z","description":"The newest immune-based therapy may be effective against triple negative breast cancer, which currently has few treatment options","url":"https://time.com/4721371/immunotherapy-triple-negative-breast-cancer/","keywords":["Cancer","Breast Cancer","immune system"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt936a5938ac00481d/698868f2cf40a8237cc4044e/breast-cancer-02.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt936a5938ac00481d/698868f2cf40a8237cc4044e/breast-cancer-02.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"breast cancer","caption":"breast cancer","creditText":"Getty Images (1); Illustration by Mia Tramz for TIME","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/cancer/","name":"Cancer"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/4721371/immunotherapy-triple-negative-breast-cancer/","name":"Immunotherapy May Treat This Deadly Breast Cancer"}}]}] ```